Maria Maccecchini
Tracked across 2 events · 14 articles · First seen Apr 02, 2026 · Last active Aug 14, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Maria Maccecchini, President and CEO of Annovis Bio, emphasized the importance of the new patent in protecting buntanetap's potential and addressing neurodegeneration from microbial and viral infections.
Apr 02, 2026 · 8 articles
Business
Annovis Bio, Inc. (NYSE: ANVS) announced on August 14, 2026, that its pivotal Phase 3 Alzheimer's disease (AD) trial has reached full enrollment with 850 patients, exceeding the original target of 760. The trial evaluates…
Impact: As President and CEO, Maria Maccecchini is the public face of the company's progress, highlighting the milestone of full enrollment and the company's readiness for regulatory submission. Her leadership is critical to the company's strategic direction.
Aug 14, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Maria Maccecchini live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard